nodes	percent_of_prediction	percent_of_DWPC	metapath
Pemetrexed—Folic Acid Metabolism Inhibitors—Methotrexate—esophageal cancer	0.318	1	CiPCiCtD
Pemetrexed—Methotrexate—esophageal cancer	0.21	1	CrCtD
Pemetrexed—lung cancer—esophageal cancer	0.16	1	CtDrD
Pemetrexed—TYMS—Capecitabine—esophageal cancer	0.0388	0.289	CbGbCtD
Pemetrexed—ATIC—Methotrexate—esophageal cancer	0.0359	0.268	CbGbCtD
Pemetrexed—SLC46A1—Methotrexate—esophageal cancer	0.0285	0.213	CbGbCtD
Pemetrexed—Tetrahydrofolic acid—Methotrexate—esophageal cancer	0.0279	0.2	CrCrCtD
Pemetrexed—Leucovorin—Methotrexate—esophageal cancer	0.0279	0.2	CrCrCtD
Pemetrexed—Folic Acid—Methotrexate—esophageal cancer	0.0279	0.2	CrCrCtD
Pemetrexed—Raltitrexed—Methotrexate—esophageal cancer	0.0279	0.2	CrCrCtD
Pemetrexed—Pralatrexate—Methotrexate—esophageal cancer	0.0279	0.2	CrCrCtD
Pemetrexed—DHFR—Methotrexate—esophageal cancer	0.0182	0.136	CbGbCtD
Pemetrexed—TYMS—Methotrexate—esophageal cancer	0.0127	0.0946	CbGbCtD
Pemetrexed—Metastases to liver—Capecitabine—esophageal cancer	0.00106	0.0696	CcSEcCtD
Pemetrexed—Hepatic cancer metastatic—Capecitabine—esophageal cancer	0.00106	0.0696	CcSEcCtD
Pemetrexed—Odynophagia—Capecitabine—esophageal cancer	0.000705	0.0462	CcSEcCtD
Pemetrexed—GART—bronchus—esophageal cancer	0.000615	0.0721	CbGeAlD
Pemetrexed—Creatinine renal clearance decreased—Capecitabine—esophageal cancer	0.000609	0.04	CcSEcCtD
Pemetrexed—GART—trachea—esophageal cancer	0.000552	0.0647	CbGeAlD
Pemetrexed—GART—digestive system—esophageal cancer	0.000475	0.0557	CbGeAlD
Pemetrexed—Mood alteration NOS—Capecitabine—esophageal cancer	0.00044	0.0289	CcSEcCtD
Pemetrexed—ATIC—epithelium—esophageal cancer	0.000424	0.0497	CbGeAlD
Pemetrexed—ATIC—smooth muscle tissue—esophageal cancer	0.000408	0.0479	CbGeAlD
Pemetrexed—GART—lung—esophageal cancer	0.000397	0.0465	CbGeAlD
Pemetrexed—SLC46A1—digestive system—esophageal cancer	0.000385	0.0452	CbGeAlD
Pemetrexed—Mood alteration NOS—Methotrexate—esophageal cancer	0.000328	0.0215	CcSEcCtD
Pemetrexed—ATIC—digestive system—esophageal cancer	0.000322	0.0378	CbGeAlD
Pemetrexed—Peripheral sensory neuropathy—Capecitabine—esophageal cancer	0.000309	0.0203	CcSEcCtD
Pemetrexed—TYMS—bronchus—esophageal cancer	0.000283	0.0332	CbGeAlD
Pemetrexed—DHFR—bronchus—esophageal cancer	0.00028	0.0329	CbGeAlD
Pemetrexed—TYMS—smooth muscle tissue—esophageal cancer	0.000277	0.0325	CbGeAlD
Pemetrexed—GART—lymph node—esophageal cancer	0.000271	0.0318	CbGeAlD
Pemetrexed—ATIC—lung—esophageal cancer	0.000269	0.0316	CbGeAlD
Pemetrexed—SLC29A1—bronchus—esophageal cancer	0.000254	0.0298	CbGeAlD
Pemetrexed—DHFR—trachea—esophageal cancer	0.000252	0.0295	CbGeAlD
Pemetrexed—DCK—bronchus—esophageal cancer	0.000242	0.0284	CbGeAlD
Pemetrexed—Arrhythmia supraventricular—Capecitabine—esophageal cancer	0.000228	0.015	CcSEcCtD
Pemetrexed—SLC29A1—trachea—esophageal cancer	0.000228	0.0267	CbGeAlD
Pemetrexed—SLC46A1—lymph node—esophageal cancer	0.00022	0.0258	CbGeAlD
Pemetrexed—TYMS—digestive system—esophageal cancer	0.000219	0.0256	CbGeAlD
Pemetrexed—DCK—trachea—esophageal cancer	0.000218	0.0255	CbGeAlD
Pemetrexed—DHFR—digestive system—esophageal cancer	0.000216	0.0254	CbGeAlD
Pemetrexed—Leucovorin—ABCC2—esophageal cancer	0.000212	0.445	CrCbGaD
Pemetrexed—Febrile neutropenia—Cisplatin—esophageal cancer	0.000199	0.0131	CcSEcCtD
Pemetrexed—SLC29A1—digestive system—esophageal cancer	0.000196	0.023	CbGeAlD
Pemetrexed—DCK—digestive system—esophageal cancer	0.000187	0.022	CbGeAlD
Pemetrexed—ATIC—lymph node—esophageal cancer	0.000184	0.0216	CbGeAlD
Pemetrexed—TYMS—lung—esophageal cancer	0.000183	0.0214	CbGeAlD
Pemetrexed—DHFR—lung—esophageal cancer	0.000181	0.0212	CbGeAlD
Pemetrexed—Transient ischaemic attack—Capecitabine—esophageal cancer	0.000175	0.0115	CcSEcCtD
Pemetrexed—Intestinal perforation—Methotrexate—esophageal cancer	0.000166	0.0109	CcSEcCtD
Pemetrexed—SLC29A1—lung—esophageal cancer	0.000164	0.0192	CbGeAlD
Pemetrexed—Mucosal inflammation—Capecitabine—esophageal cancer	0.00016	0.0105	CcSEcCtD
Pemetrexed—DCK—lung—esophageal cancer	0.000156	0.0184	CbGeAlD
Pemetrexed—Platelet count decreased—Capecitabine—esophageal cancer	0.000149	0.00975	CcSEcCtD
Pemetrexed—Febrile neutropenia—Capecitabine—esophageal cancer	0.000147	0.00964	CcSEcCtD
Pemetrexed—Infection—Carboplatin—esophageal cancer	0.000145	0.00951	CcSEcCtD
Pemetrexed—Nephropathy—Methotrexate—esophageal cancer	0.000138	0.00907	CcSEcCtD
Pemetrexed—Embolism—Capecitabine—esophageal cancer	0.000138	0.00903	CcSEcCtD
Pemetrexed—Tetrahydrofolic acid—ABCC2—esophageal cancer	0.000137	0.287	CrCbGaD
Pemetrexed—Interstitial pneumonia—Methotrexate—esophageal cancer	0.000136	0.00893	CcSEcCtD
Pemetrexed—Haemoglobin decreased—Capecitabine—esophageal cancer	0.000128	0.00843	CcSEcCtD
Pemetrexed—TYMS—lymph node—esophageal cancer	0.000125	0.0147	CbGeAlD
Pemetrexed—Thrombosis—Capecitabine—esophageal cancer	0.000125	0.00819	CcSEcCtD
Pemetrexed—Pain—Carboplatin—esophageal cancer	0.000125	0.00818	CcSEcCtD
Pemetrexed—DHFR—lymph node—esophageal cancer	0.000124	0.0145	CbGeAlD
Pemetrexed—Mucosal inflammation—Methotrexate—esophageal cancer	0.000119	0.0078	CcSEcCtD
Pemetrexed—Body temperature increased—Carboplatin—esophageal cancer	0.000115	0.00756	CcSEcCtD
Pemetrexed—Skin exfoliation—Cisplatin—esophageal cancer	0.000114	0.00751	CcSEcCtD
Pemetrexed—Neuropathy—Cisplatin—esophageal cancer	0.000113	0.00739	CcSEcCtD
Pemetrexed—SLC29A1—lymph node—esophageal cancer	0.000112	0.0131	CbGeAlD
Pemetrexed—Myocardial ischaemia—Capecitabine—esophageal cancer	0.00011	0.00721	CcSEcCtD
Pemetrexed—Febrile neutropenia—Methotrexate—esophageal cancer	0.000109	0.00718	CcSEcCtD
Pemetrexed—DCK—lymph node—esophageal cancer	0.000107	0.0126	CbGeAlD
Pemetrexed—Embolism—Methotrexate—esophageal cancer	0.000102	0.00673	CcSEcCtD
Pemetrexed—Rectal haemorrhage—Capecitabine—esophageal cancer	9.79e-05	0.00642	CcSEcCtD
Pemetrexed—Haemolytic anaemia—Cisplatin—esophageal cancer	9.64e-05	0.00633	CcSEcCtD
Pemetrexed—Lacrimation increased—Capecitabine—esophageal cancer	9.59e-05	0.00629	CcSEcCtD
Pemetrexed—Renal failure acute—Cisplatin—esophageal cancer	9.43e-05	0.00619	CcSEcCtD
Pemetrexed—Methotrexate—ABCC2—esophageal cancer	9.35e-05	0.196	CrCbGaD
Pemetrexed—Interstitial lung disease—Methotrexate—esophageal cancer	9.3e-05	0.0061	CcSEcCtD
Pemetrexed—Cerebrovascular accident—Cisplatin—esophageal cancer	8.88e-05	0.00583	CcSEcCtD
Pemetrexed—Pulmonary embolism—Capecitabine—esophageal cancer	8.84e-05	0.0058	CcSEcCtD
Pemetrexed—Colitis—Capecitabine—esophageal cancer	8.49e-05	0.00557	CcSEcCtD
Pemetrexed—Skin exfoliation—Capecitabine—esophageal cancer	8.44e-05	0.00554	CcSEcCtD
Pemetrexed—Neuropathy—Capecitabine—esophageal cancer	8.3e-05	0.00544	CcSEcCtD
Pemetrexed—Blood creatinine increased—Cisplatin—esophageal cancer	8.15e-05	0.00535	CcSEcCtD
Pemetrexed—Dehydration—Cisplatin—esophageal cancer	8.09e-05	0.00531	CcSEcCtD
Pemetrexed—Oesophagitis—Capecitabine—esophageal cancer	8.08e-05	0.0053	CcSEcCtD
Pemetrexed—Aspartate aminotransferase increased—Cisplatin—esophageal cancer	7.84e-05	0.00514	CcSEcCtD
Pemetrexed—Sepsis—Capecitabine—esophageal cancer	7.67e-05	0.00503	CcSEcCtD
Pemetrexed—Pancreatitis—Cisplatin—esophageal cancer	7.38e-05	0.00484	CcSEcCtD
Pemetrexed—Pancytopenia—Cisplatin—esophageal cancer	7.14e-05	0.00469	CcSEcCtD
Pemetrexed—Haemolytic anaemia—Capecitabine—esophageal cancer	7.11e-05	0.00466	CcSEcCtD
Pemetrexed—Renal failure acute—Capecitabine—esophageal cancer	6.95e-05	0.00456	CcSEcCtD
Pemetrexed—Respiratory failure—Methotrexate—esophageal cancer	6.7e-05	0.0044	CcSEcCtD
Pemetrexed—Acute coronary syndrome—Cisplatin—esophageal cancer	6.61e-05	0.00434	CcSEcCtD
Pemetrexed—Renal failure—Cisplatin—esophageal cancer	6.59e-05	0.00433	CcSEcCtD
Pemetrexed—Pulmonary embolism—Methotrexate—esophageal cancer	6.58e-05	0.00432	CcSEcCtD
Pemetrexed—Myocardial infarction—Cisplatin—esophageal cancer	6.57e-05	0.00431	CcSEcCtD
Pemetrexed—Neuropathy peripheral—Cisplatin—esophageal cancer	6.57e-05	0.00431	CcSEcCtD
Pemetrexed—Cerebrovascular accident—Capecitabine—esophageal cancer	6.55e-05	0.0043	CcSEcCtD
Pemetrexed—Stomatitis—Cisplatin—esophageal cancer	6.54e-05	0.00429	CcSEcCtD
Pemetrexed—Conjunctivitis—Cisplatin—esophageal cancer	6.52e-05	0.00428	CcSEcCtD
Pemetrexed—Hepatobiliary disease—Cisplatin—esophageal cancer	6.34e-05	0.00416	CcSEcCtD
Pemetrexed—Skin exfoliation—Methotrexate—esophageal cancer	6.28e-05	0.00412	CcSEcCtD
Pemetrexed—Mood swings—Capecitabine—esophageal cancer	6.08e-05	0.00399	CcSEcCtD
Pemetrexed—Blood creatinine increased—Capecitabine—esophageal cancer	6.01e-05	0.00394	CcSEcCtD
Pemetrexed—Dehydration—Capecitabine—esophageal cancer	5.97e-05	0.00391	CcSEcCtD
Pemetrexed—Urinary tract disorder—Cisplatin—esophageal cancer	5.95e-05	0.0039	CcSEcCtD
Pemetrexed—Urethral disorder—Cisplatin—esophageal cancer	5.9e-05	0.00387	CcSEcCtD
Pemetrexed—Aspartate aminotransferase increased—Capecitabine—esophageal cancer	5.78e-05	0.00379	CcSEcCtD
Pemetrexed—Toxic epidermal necrolysis—Capecitabine—esophageal cancer	5.78e-05	0.00379	CcSEcCtD
Pemetrexed—Sepsis—Methotrexate—esophageal cancer	5.71e-05	0.00375	CcSEcCtD
Pemetrexed—Alanine aminotransferase increased—Capecitabine—esophageal cancer	5.66e-05	0.00371	CcSEcCtD
Pemetrexed—Eye disorder—Cisplatin—esophageal cancer	5.63e-05	0.00369	CcSEcCtD
Pemetrexed—Dysphagia—Capecitabine—esophageal cancer	5.55e-05	0.00364	CcSEcCtD
Pemetrexed—Angina pectoris—Capecitabine—esophageal cancer	5.4e-05	0.00354	CcSEcCtD
Pemetrexed—Arrhythmia—Cisplatin—esophageal cancer	5.38e-05	0.00353	CcSEcCtD
Pemetrexed—Alopecia—Cisplatin—esophageal cancer	5.32e-05	0.00349	CcSEcCtD
Pemetrexed—Pancytopenia—Capecitabine—esophageal cancer	5.27e-05	0.00346	CcSEcCtD
Pemetrexed—Erythema—Cisplatin—esophageal cancer	5.24e-05	0.00344	CcSEcCtD
Pemetrexed—Malnutrition—Cisplatin—esophageal cancer	5.24e-05	0.00344	CcSEcCtD
Pemetrexed—Neutropenia—Capecitabine—esophageal cancer	5.19e-05	0.0034	CcSEcCtD
Pemetrexed—Renal failure acute—Methotrexate—esophageal cancer	5.17e-05	0.00339	CcSEcCtD
Pemetrexed—Infestation NOS—Capecitabine—esophageal cancer	4.94e-05	0.00324	CcSEcCtD
Pemetrexed—Infestation—Capecitabine—esophageal cancer	4.94e-05	0.00324	CcSEcCtD
Pemetrexed—Stevens-Johnson syndrome—Capecitabine—esophageal cancer	4.9e-05	0.00322	CcSEcCtD
Pemetrexed—Acute coronary syndrome—Capecitabine—esophageal cancer	4.87e-05	0.0032	CcSEcCtD
Pemetrexed—Cerebrovascular accident—Methotrexate—esophageal cancer	4.87e-05	0.0032	CcSEcCtD
Pemetrexed—Renal failure—Capecitabine—esophageal cancer	4.86e-05	0.00319	CcSEcCtD
Pemetrexed—Myocardial infarction—Capecitabine—esophageal cancer	4.85e-05	0.00318	CcSEcCtD
Pemetrexed—Neuropathy peripheral—Capecitabine—esophageal cancer	4.85e-05	0.00318	CcSEcCtD
Pemetrexed—Anaemia—Cisplatin—esophageal cancer	4.84e-05	0.00318	CcSEcCtD
Pemetrexed—Stomatitis—Capecitabine—esophageal cancer	4.82e-05	0.00316	CcSEcCtD
Pemetrexed—Conjunctivitis—Capecitabine—esophageal cancer	4.81e-05	0.00315	CcSEcCtD
Pemetrexed—Leukopenia—Cisplatin—esophageal cancer	4.69e-05	0.00308	CcSEcCtD
Pemetrexed—Hepatobiliary disease—Capecitabine—esophageal cancer	4.68e-05	0.00307	CcSEcCtD
Pemetrexed—Agranulocytosis—Capecitabine—esophageal cancer	4.61e-05	0.00303	CcSEcCtD
Pemetrexed—Mood swings—Methotrexate—esophageal cancer	4.52e-05	0.00297	CcSEcCtD
Pemetrexed—Myalgia—Cisplatin—esophageal cancer	4.46e-05	0.00293	CcSEcCtD
Pemetrexed—Hepatitis—Capecitabine—esophageal cancer	4.44e-05	0.00291	CcSEcCtD
Pemetrexed—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	4.43e-05	0.00291	CcSEcCtD
Pemetrexed—Pharyngitis—Capecitabine—esophageal cancer	4.41e-05	0.00289	CcSEcCtD
Pemetrexed—Urinary tract disorder—Capecitabine—esophageal cancer	4.38e-05	0.00288	CcSEcCtD
Pemetrexed—Urethral disorder—Capecitabine—esophageal cancer	4.35e-05	0.00285	CcSEcCtD
Pemetrexed—Toxic epidermal necrolysis—Methotrexate—esophageal cancer	4.3e-05	0.00282	CcSEcCtD
Pemetrexed—Oedema—Cisplatin—esophageal cancer	4.28e-05	0.00281	CcSEcCtD
Pemetrexed—Anaphylactic shock—Cisplatin—esophageal cancer	4.28e-05	0.00281	CcSEcCtD
Pemetrexed—Infection—Cisplatin—esophageal cancer	4.25e-05	0.00279	CcSEcCtD
Pemetrexed—Erythema multiforme—Capecitabine—esophageal cancer	4.2e-05	0.00275	CcSEcCtD
Pemetrexed—Nervous system disorder—Cisplatin—esophageal cancer	4.2e-05	0.00275	CcSEcCtD
Pemetrexed—Thrombocytopenia—Cisplatin—esophageal cancer	4.19e-05	0.00275	CcSEcCtD
Pemetrexed—Skin disorder—Cisplatin—esophageal cancer	4.16e-05	0.00273	CcSEcCtD
Pemetrexed—Eye disorder—Capecitabine—esophageal cancer	4.15e-05	0.00272	CcSEcCtD
Pemetrexed—Anorexia—Cisplatin—esophageal cancer	4.08e-05	0.00268	CcSEcCtD
Pemetrexed—Pancreatitis—Methotrexate—esophageal cancer	4.05e-05	0.00266	CcSEcCtD
Pemetrexed—Arrhythmia—Capecitabine—esophageal cancer	3.97e-05	0.0026	CcSEcCtD
Pemetrexed—Alopecia—Capecitabine—esophageal cancer	3.92e-05	0.00257	CcSEcCtD
Pemetrexed—Pancytopenia—Methotrexate—esophageal cancer	3.92e-05	0.00257	CcSEcCtD
Pemetrexed—Musculoskeletal discomfort—Cisplatin—esophageal cancer	3.9e-05	0.00256	CcSEcCtD
Pemetrexed—Erythema—Capecitabine—esophageal cancer	3.86e-05	0.00254	CcSEcCtD
Pemetrexed—Malnutrition—Capecitabine—esophageal cancer	3.86e-05	0.00254	CcSEcCtD
Pemetrexed—Neutropenia—Methotrexate—esophageal cancer	3.86e-05	0.00253	CcSEcCtD
Pemetrexed—Dyspnoea—Cisplatin—esophageal cancer	3.81e-05	0.0025	CcSEcCtD
Pemetrexed—Dysgeusia—Capecitabine—esophageal cancer	3.78e-05	0.00248	CcSEcCtD
Pemetrexed—Decreased appetite—Cisplatin—esophageal cancer	3.72e-05	0.00244	CcSEcCtD
Pemetrexed—Gastrointestinal disorder—Cisplatin—esophageal cancer	3.69e-05	0.00242	CcSEcCtD
Pemetrexed—Infestation—Methotrexate—esophageal cancer	3.68e-05	0.00242	CcSEcCtD
Pemetrexed—Infestation NOS—Methotrexate—esophageal cancer	3.68e-05	0.00242	CcSEcCtD
Pemetrexed—Pain—Cisplatin—esophageal cancer	3.66e-05	0.0024	CcSEcCtD
Pemetrexed—Stevens-Johnson syndrome—Methotrexate—esophageal cancer	3.65e-05	0.00239	CcSEcCtD
Pemetrexed—Renal failure—Methotrexate—esophageal cancer	3.62e-05	0.00237	CcSEcCtD
Pemetrexed—Stomatitis—Methotrexate—esophageal cancer	3.59e-05	0.00235	CcSEcCtD
Pemetrexed—Conjunctivitis—Methotrexate—esophageal cancer	3.58e-05	0.00235	CcSEcCtD
Pemetrexed—Anaemia—Capecitabine—esophageal cancer	3.57e-05	0.00234	CcSEcCtD
Pemetrexed—Hepatobiliary disease—Methotrexate—esophageal cancer	3.48e-05	0.00228	CcSEcCtD
Pemetrexed—Syncope—Capecitabine—esophageal cancer	3.46e-05	0.00227	CcSEcCtD
Pemetrexed—Leukopenia—Capecitabine—esophageal cancer	3.46e-05	0.00227	CcSEcCtD
Pemetrexed—Methotrexate—ABCB1—esophageal cancer	3.44e-05	0.0722	CrCbGaD
Pemetrexed—Agranulocytosis—Methotrexate—esophageal cancer	3.43e-05	0.00225	CcSEcCtD
Pemetrexed—Loss of consciousness—Capecitabine—esophageal cancer	3.4e-05	0.00223	CcSEcCtD
Pemetrexed—Body temperature increased—Cisplatin—esophageal cancer	3.38e-05	0.00222	CcSEcCtD
Pemetrexed—Hypertension—Capecitabine—esophageal cancer	3.34e-05	0.00219	CcSEcCtD
Pemetrexed—Hepatitis—Methotrexate—esophageal cancer	3.3e-05	0.00217	CcSEcCtD
Pemetrexed—Chest pain—Capecitabine—esophageal cancer	3.29e-05	0.00216	CcSEcCtD
Pemetrexed—Myalgia—Capecitabine—esophageal cancer	3.29e-05	0.00216	CcSEcCtD
Pemetrexed—Arthralgia—Capecitabine—esophageal cancer	3.29e-05	0.00216	CcSEcCtD
Pemetrexed—Pharyngitis—Methotrexate—esophageal cancer	3.28e-05	0.00215	CcSEcCtD
Pemetrexed—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	3.27e-05	0.00214	CcSEcCtD
Pemetrexed—Urinary tract disorder—Methotrexate—esophageal cancer	3.26e-05	0.00214	CcSEcCtD
Pemetrexed—Urethral disorder—Methotrexate—esophageal cancer	3.24e-05	0.00213	CcSEcCtD
Pemetrexed—Oedema—Capecitabine—esophageal cancer	3.15e-05	0.00207	CcSEcCtD
Pemetrexed—Hypersensitivity—Cisplatin—esophageal cancer	3.15e-05	0.00207	CcSEcCtD
Pemetrexed—Infection—Capecitabine—esophageal cancer	3.13e-05	0.00206	CcSEcCtD
Pemetrexed—Erythema multiforme—Methotrexate—esophageal cancer	3.12e-05	0.00205	CcSEcCtD
Pemetrexed—Shock—Capecitabine—esophageal cancer	3.1e-05	0.00204	CcSEcCtD
Pemetrexed—Nervous system disorder—Capecitabine—esophageal cancer	3.09e-05	0.00203	CcSEcCtD
Pemetrexed—Eye disorder—Methotrexate—esophageal cancer	3.09e-05	0.00203	CcSEcCtD
Pemetrexed—Thrombocytopenia—Capecitabine—esophageal cancer	3.09e-05	0.00203	CcSEcCtD
Pemetrexed—Asthenia—Cisplatin—esophageal cancer	3.07e-05	0.00201	CcSEcCtD
Pemetrexed—Skin disorder—Capecitabine—esophageal cancer	3.06e-05	0.00201	CcSEcCtD
Pemetrexed—Anorexia—Capecitabine—esophageal cancer	3.01e-05	0.00197	CcSEcCtD
Pemetrexed—Diarrhoea—Cisplatin—esophageal cancer	2.93e-05	0.00192	CcSEcCtD
Pemetrexed—Alopecia—Methotrexate—esophageal cancer	2.92e-05	0.00192	CcSEcCtD
Pemetrexed—Erythema—Methotrexate—esophageal cancer	2.88e-05	0.00189	CcSEcCtD
Pemetrexed—Malnutrition—Methotrexate—esophageal cancer	2.88e-05	0.00189	CcSEcCtD
Pemetrexed—Musculoskeletal discomfort—Capecitabine—esophageal cancer	2.87e-05	0.00189	CcSEcCtD
Pemetrexed—Dysgeusia—Methotrexate—esophageal cancer	2.82e-05	0.00185	CcSEcCtD
Pemetrexed—Dyspnoea—Capecitabine—esophageal cancer	2.81e-05	0.00184	CcSEcCtD
Pemetrexed—Dyspepsia—Capecitabine—esophageal cancer	2.78e-05	0.00182	CcSEcCtD
Pemetrexed—Decreased appetite—Capecitabine—esophageal cancer	2.74e-05	0.0018	CcSEcCtD
Pemetrexed—Gastrointestinal disorder—Capecitabine—esophageal cancer	2.72e-05	0.00179	CcSEcCtD
Pemetrexed—Vomiting—Cisplatin—esophageal cancer	2.72e-05	0.00178	CcSEcCtD
Pemetrexed—Fatigue—Capecitabine—esophageal cancer	2.72e-05	0.00178	CcSEcCtD
Pemetrexed—Rash—Cisplatin—esophageal cancer	2.7e-05	0.00177	CcSEcCtD
Pemetrexed—Pain—Capecitabine—esophageal cancer	2.7e-05	0.00177	CcSEcCtD
Pemetrexed—Constipation—Capecitabine—esophageal cancer	2.7e-05	0.00177	CcSEcCtD
Pemetrexed—Dermatitis—Cisplatin—esophageal cancer	2.69e-05	0.00177	CcSEcCtD
Pemetrexed—Anaemia—Methotrexate—esophageal cancer	2.66e-05	0.00174	CcSEcCtD
Pemetrexed—Gastrointestinal pain—Capecitabine—esophageal cancer	2.58e-05	0.00169	CcSEcCtD
Pemetrexed—Leukopenia—Methotrexate—esophageal cancer	2.57e-05	0.00169	CcSEcCtD
Pemetrexed—Nausea—Cisplatin—esophageal cancer	2.54e-05	0.00167	CcSEcCtD
Pemetrexed—Urticaria—Capecitabine—esophageal cancer	2.51e-05	0.00164	CcSEcCtD
Pemetrexed—Abdominal pain—Capecitabine—esophageal cancer	2.49e-05	0.00164	CcSEcCtD
Pemetrexed—Body temperature increased—Capecitabine—esophageal cancer	2.49e-05	0.00164	CcSEcCtD
Pemetrexed—Arthralgia—Methotrexate—esophageal cancer	2.45e-05	0.00161	CcSEcCtD
Pemetrexed—Chest pain—Methotrexate—esophageal cancer	2.45e-05	0.00161	CcSEcCtD
Pemetrexed—Myalgia—Methotrexate—esophageal cancer	2.45e-05	0.00161	CcSEcCtD
Pemetrexed—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	2.43e-05	0.0016	CcSEcCtD
Pemetrexed—Anaphylactic shock—Methotrexate—esophageal cancer	2.35e-05	0.00154	CcSEcCtD
Pemetrexed—Infection—Methotrexate—esophageal cancer	2.33e-05	0.00153	CcSEcCtD
Pemetrexed—Hypersensitivity—Capecitabine—esophageal cancer	2.32e-05	0.00152	CcSEcCtD
Pemetrexed—Nervous system disorder—Methotrexate—esophageal cancer	2.3e-05	0.00151	CcSEcCtD
Pemetrexed—Thrombocytopenia—Methotrexate—esophageal cancer	2.3e-05	0.00151	CcSEcCtD
Pemetrexed—Skin disorder—Methotrexate—esophageal cancer	2.28e-05	0.0015	CcSEcCtD
Pemetrexed—Asthenia—Capecitabine—esophageal cancer	2.26e-05	0.00148	CcSEcCtD
Pemetrexed—Anorexia—Methotrexate—esophageal cancer	2.24e-05	0.00147	CcSEcCtD
Pemetrexed—Pruritus—Capecitabine—esophageal cancer	2.23e-05	0.00146	CcSEcCtD
Pemetrexed—Diarrhoea—Capecitabine—esophageal cancer	2.16e-05	0.00142	CcSEcCtD
Pemetrexed—Musculoskeletal discomfort—Methotrexate—esophageal cancer	2.14e-05	0.0014	CcSEcCtD
Pemetrexed—Dyspnoea—Methotrexate—esophageal cancer	2.09e-05	0.00137	CcSEcCtD
Pemetrexed—Dizziness—Capecitabine—esophageal cancer	2.09e-05	0.00137	CcSEcCtD
Pemetrexed—Dyspepsia—Methotrexate—esophageal cancer	2.07e-05	0.00136	CcSEcCtD
Pemetrexed—Decreased appetite—Methotrexate—esophageal cancer	2.04e-05	0.00134	CcSEcCtD
Pemetrexed—Gastrointestinal disorder—Methotrexate—esophageal cancer	2.03e-05	0.00133	CcSEcCtD
Pemetrexed—Fatigue—Methotrexate—esophageal cancer	2.02e-05	0.00133	CcSEcCtD
Pemetrexed—Pain—Methotrexate—esophageal cancer	2.01e-05	0.00132	CcSEcCtD
Pemetrexed—Vomiting—Capecitabine—esophageal cancer	2e-05	0.00132	CcSEcCtD
Pemetrexed—Rash—Capecitabine—esophageal cancer	1.99e-05	0.0013	CcSEcCtD
Pemetrexed—Dermatitis—Capecitabine—esophageal cancer	1.99e-05	0.0013	CcSEcCtD
Pemetrexed—Gastrointestinal pain—Methotrexate—esophageal cancer	1.92e-05	0.00126	CcSEcCtD
Pemetrexed—Nausea—Capecitabine—esophageal cancer	1.87e-05	0.00123	CcSEcCtD
Pemetrexed—Urticaria—Methotrexate—esophageal cancer	1.86e-05	0.00122	CcSEcCtD
Pemetrexed—Abdominal pain—Methotrexate—esophageal cancer	1.86e-05	0.00122	CcSEcCtD
Pemetrexed—Body temperature increased—Methotrexate—esophageal cancer	1.86e-05	0.00122	CcSEcCtD
Pemetrexed—Hypersensitivity—Methotrexate—esophageal cancer	1.73e-05	0.00113	CcSEcCtD
Pemetrexed—Asthenia—Methotrexate—esophageal cancer	1.68e-05	0.00111	CcSEcCtD
Pemetrexed—Pruritus—Methotrexate—esophageal cancer	1.66e-05	0.00109	CcSEcCtD
Pemetrexed—Diarrhoea—Methotrexate—esophageal cancer	1.61e-05	0.00105	CcSEcCtD
Pemetrexed—TYMS—Retinoblastoma (RB) in Cancer—MYC—esophageal cancer	1.58e-05	0.00112	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—CA2—esophageal cancer	1.58e-05	0.00112	CbGpPWpGaD
Pemetrexed—GART—Metabolism—ABCB1—esophageal cancer	1.57e-05	0.00111	CbGpPWpGaD
Pemetrexed—Dizziness—Methotrexate—esophageal cancer	1.55e-05	0.00102	CcSEcCtD
Pemetrexed—ATIC—Metabolism—ENO1—esophageal cancer	1.55e-05	0.0011	CbGpPWpGaD
Pemetrexed—ATIC—Metabolism—PTGS1—esophageal cancer	1.55e-05	0.0011	CbGpPWpGaD
Pemetrexed—DHFR—Mitotic G1-G1/S phases—CDKN1A—esophageal cancer	1.54e-05	0.00109	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—GAPDH—esophageal cancer	1.54e-05	0.00109	CbGpPWpGaD
Pemetrexed—ATIC—Metabolism—PSME1—esophageal cancer	1.53e-05	0.00108	CbGpPWpGaD
Pemetrexed—ATIC—Metabolism—PSME2—esophageal cancer	1.53e-05	0.00108	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—CRABP1—esophageal cancer	1.52e-05	0.00108	CbGpPWpGaD
Pemetrexed—TYMS—Circadian rythm related genes—NOS2—esophageal cancer	1.52e-05	0.00108	CbGpPWpGaD
Pemetrexed—DHFR—G1/S Transition—MYC—esophageal cancer	1.52e-05	0.00108	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle, Mitotic—BUB1B—esophageal cancer	1.51e-05	0.00107	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—B2M—esophageal cancer	1.51e-05	0.00107	CbGpPWpGaD
Pemetrexed—SLC29A1—Transmembrane transport of small molecules—HMOX1—esophageal cancer	1.49e-05	0.00106	CbGpPWpGaD
Pemetrexed—Vomiting—Methotrexate—esophageal cancer	1.49e-05	0.000979	CcSEcCtD
Pemetrexed—DHFR—Retinoblastoma (RB) in Cancer—TP53—esophageal cancer	1.49e-05	0.00106	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle—PSME2—esophageal cancer	1.49e-05	0.00105	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle—PSME1—esophageal cancer	1.49e-05	0.00105	CbGpPWpGaD
Pemetrexed—Rash—Methotrexate—esophageal cancer	1.48e-05	0.000971	CcSEcCtD
Pemetrexed—Dermatitis—Methotrexate—esophageal cancer	1.48e-05	0.00097	CcSEcCtD
Pemetrexed—TYMS—Cell Cycle—MAD2L1—esophageal cancer	1.48e-05	0.00105	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—PLCE1—esophageal cancer	1.46e-05	0.00104	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—ADH7—esophageal cancer	1.46e-05	0.00104	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle, Mitotic—PSME2—esophageal cancer	1.45e-05	0.00103	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle, Mitotic—PSME1—esophageal cancer	1.45e-05	0.00103	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—GNG7—esophageal cancer	1.45e-05	0.00103	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—ENO1—esophageal cancer	1.44e-05	0.00102	CbGpPWpGaD
Pemetrexed—DHFR—Disease—FKBP1A—esophageal cancer	1.44e-05	0.00102	CbGpPWpGaD
Pemetrexed—SLC29A1—Transmembrane transport of small molecules—ABCB1—esophageal cancer	1.43e-05	0.00102	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—CASP8—esophageal cancer	1.43e-05	0.00101	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—CREBBP—esophageal cancer	1.42e-05	0.00101	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—PSME1—esophageal cancer	1.42e-05	0.00101	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—PSME2—esophageal cancer	1.42e-05	0.00101	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—BLVRB—esophageal cancer	1.42e-05	0.00101	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—SLC52A3—esophageal cancer	1.42e-05	0.00101	CbGpPWpGaD
Pemetrexed—DHFR—Disease—DOCK2—esophageal cancer	1.41e-05	0.000997	CbGpPWpGaD
Pemetrexed—DHFR—Disease—WIF1—esophageal cancer	1.41e-05	0.000997	CbGpPWpGaD
Pemetrexed—Nausea—Methotrexate—esophageal cancer	1.39e-05	0.000915	CcSEcCtD
Pemetrexed—TYMS—Mitotic G1-G1/S phases—CCND1—esophageal cancer	1.39e-05	0.000986	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—SLC10A2—esophageal cancer	1.38e-05	0.000982	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—CA1—esophageal cancer	1.38e-05	0.000982	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—CALR—esophageal cancer	1.36e-05	0.000968	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—ALDH2—esophageal cancer	1.36e-05	0.000962	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle—BUB1B—esophageal cancer	1.35e-05	0.00096	CbGpPWpGaD
Pemetrexed—TYMS—Mitotic G1-G1/S phases—CDKN1A—esophageal cancer	1.34e-05	0.000954	CbGpPWpGaD
Pemetrexed—TYMS—G1/S Transition—MYC—esophageal cancer	1.32e-05	0.000938	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle, Mitotic—BUB1B—esophageal cancer	1.32e-05	0.000936	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—FBXW7—esophageal cancer	1.32e-05	0.000936	CbGpPWpGaD
Pemetrexed—ATIC—Metabolism—CYP1B1—esophageal cancer	1.32e-05	0.000936	CbGpPWpGaD
Pemetrexed—TYMS—Retinoblastoma (RB) in Cancer—TP53—esophageal cancer	1.3e-05	0.000923	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—PSME2—esophageal cancer	1.3e-05	0.00092	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—PSME1—esophageal cancer	1.3e-05	0.00092	CbGpPWpGaD
Pemetrexed—DHFR—Disease—CSNK1A1—esophageal cancer	1.3e-05	0.00092	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—GSTT1—esophageal cancer	1.29e-05	0.000915	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle—CHEK2—esophageal cancer	1.29e-05	0.000913	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—ADH1B—esophageal cancer	1.28e-05	0.000911	CbGpPWpGaD
Pemetrexed—DHFR—Mitotic G1-G1/S phases—MYC—esophageal cancer	1.28e-05	0.000906	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—CYP2A6—esophageal cancer	1.28e-05	0.000904	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—CA2—esophageal cancer	1.27e-05	0.000898	CbGpPWpGaD
Pemetrexed—ATIC—Metabolism—CYP19A1—esophageal cancer	1.24e-05	0.00088	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—TYMP—esophageal cancer	1.23e-05	0.00087	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—BCL2—esophageal cancer	1.23e-05	0.00087	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—ENO1—esophageal cancer	1.21e-05	0.000857	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—PTGS1—esophageal cancer	1.21e-05	0.000857	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—SLC10A2—esophageal cancer	1.21e-05	0.000857	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—CA1—esophageal cancer	1.21e-05	0.000857	CbGpPWpGaD
Pemetrexed—SLC46A1—Transmembrane transport of small molecules—CREBBP—esophageal cancer	1.21e-05	0.000857	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—CYP26A1—esophageal cancer	1.19e-05	0.000847	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—ERBB2—esophageal cancer	1.19e-05	0.000845	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—PSME2—esophageal cancer	1.19e-05	0.000845	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—PSME1—esophageal cancer	1.19e-05	0.000845	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—BUB1B—esophageal cancer	1.18e-05	0.000837	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—PLCE1—esophageal cancer	1.18e-05	0.000835	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—ADH7—esophageal cancer	1.18e-05	0.000835	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—PTGS2—esophageal cancer	1.17e-05	0.000826	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—ALOX15—esophageal cancer	1.16e-05	0.000825	CbGpPWpGaD
Pemetrexed—ATIC—Metabolism—HMOX1—esophageal cancer	1.13e-05	0.000803	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—CHEK2—esophageal cancer	1.12e-05	0.000796	CbGpPWpGaD
Pemetrexed—TYMS—Mitotic G1-G1/S phases—MYC—esophageal cancer	1.11e-05	0.000791	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—TPI1—esophageal cancer	1.11e-05	0.000787	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—GSTO1—esophageal cancer	1.11e-05	0.000787	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—CA2—esophageal cancer	1.1e-05	0.000783	CbGpPWpGaD
Pemetrexed—DHFR—Disease—ELMO1—esophageal cancer	1.09e-05	0.000773	CbGpPWpGaD
Pemetrexed—ATIC—Metabolism—ABCB1—esophageal cancer	1.09e-05	0.00077	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—TGFBR2—esophageal cancer	1.07e-05	0.000757	CbGpPWpGaD
Pemetrexed—DHFR—Disease—TPI1—esophageal cancer	1.07e-05	0.000755	CbGpPWpGaD
Pemetrexed—DHFR—Disease—GSTO1—esophageal cancer	1.07e-05	0.000755	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—ALDOB—esophageal cancer	1.06e-05	0.000755	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—CCND1—esophageal cancer	1.05e-05	0.000747	CbGpPWpGaD
Pemetrexed—GART—Metabolism—CREBBP—esophageal cancer	1.05e-05	0.000743	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—ADH1B—esophageal cancer	1.03e-05	0.000732	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—CYP1B1—esophageal cancer	1.03e-05	0.000729	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—PLCE1—esophageal cancer	1.03e-05	0.000728	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—ADH7—esophageal cancer	1.03e-05	0.000728	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—GAPDH—esophageal cancer	1.02e-05	0.000726	CbGpPWpGaD
Pemetrexed—DHFR—Disease—ALDOB—esophageal cancer	1.02e-05	0.000724	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—CDKN1A—esophageal cancer	1.02e-05	0.000722	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—CRABP1—esophageal cancer	1.02e-05	0.00072	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—SMAD4—esophageal cancer	1.01e-05	0.000717	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—TYMP—esophageal cancer	9.86e-06	0.0007	CbGpPWpGaD
Pemetrexed—DHFR—Disease—HIST1H2BM—esophageal cancer	9.83e-06	0.000697	CbGpPWpGaD
Pemetrexed—DHFR—Disease—GAPDH—esophageal cancer	9.83e-06	0.000697	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—EP300—esophageal cancer	9.69e-06	0.000687	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—CYP19A1—esophageal cancer	9.66e-06	0.000685	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—GNG7—esophageal cancer	9.66e-06	0.000685	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—CYP26A1—esophageal cancer	9.6e-06	0.00068	CbGpPWpGaD
Pemetrexed—SLC29A1—Transmembrane transport of small molecules—CREBBP—esophageal cancer	9.58e-06	0.000679	CbGpPWpGaD
Pemetrexed—GART—Metabolism—NOS3—esophageal cancer	9.38e-06	0.000665	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—ALOX15—esophageal cancer	9.35e-06	0.000663	CbGpPWpGaD
Pemetrexed—TYMS—Circadian rythm related genes—EP300—esophageal cancer	9.3e-06	0.00066	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—ALDH2—esophageal cancer	9.05e-06	0.000642	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—ADH1B—esophageal cancer	9.01e-06	0.000639	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—GSTO1—esophageal cancer	8.92e-06	0.000633	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—TPI1—esophageal cancer	8.92e-06	0.000633	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—HMOX1—esophageal cancer	8.82e-06	0.000625	CbGpPWpGaD
Pemetrexed—DHFR—Disease—XIAP—esophageal cancer	8.68e-06	0.000616	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—TYMP—esophageal cancer	8.61e-06	0.00061	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—GSTT1—esophageal cancer	8.61e-06	0.00061	CbGpPWpGaD
Pemetrexed—GART—Metabolism—PTGS2—esophageal cancer	8.58e-06	0.000608	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—ALDOB—esophageal cancer	8.55e-06	0.000607	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—CYP2A6—esophageal cancer	8.51e-06	0.000603	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—ABCB1—esophageal cancer	8.46e-06	0.0006	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—MYC—esophageal cancer	8.45e-06	0.000599	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—CYP26A1—esophageal cancer	8.37e-06	0.000594	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—HIF1A—esophageal cancer	8.27e-06	0.000586	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—EGFR—esophageal cancer	8.26e-06	0.000586	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—GAPDH—esophageal cancer	8.23e-06	0.000584	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—ALOX15—esophageal cancer	8.16e-06	0.000579	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—CRABP1—esophageal cancer	8.16e-06	0.000579	CbGpPWpGaD
Pemetrexed—DHFR—Disease—B2M—esophageal cancer	8.07e-06	0.000572	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—PTGS1—esophageal cancer	8.07e-06	0.000572	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—ENO1—esophageal cancer	8.07e-06	0.000572	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—PSME2—esophageal cancer	7.95e-06	0.000564	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—PSME1—esophageal cancer	7.95e-06	0.000564	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle, Mitotic—RB1—esophageal cancer	7.87e-06	0.000558	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—TPI1—esophageal cancer	7.78e-06	0.000552	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—GSTO1—esophageal cancer	7.78e-06	0.000552	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—GNG7—esophageal cancer	7.76e-06	0.00055	CbGpPWpGaD
Pemetrexed—DHFR—Disease—ENO1—esophageal cancer	7.74e-06	0.000549	CbGpPWpGaD
Pemetrexed—DHFR—Disease—PSME2—esophageal cancer	7.63e-06	0.000541	CbGpPWpGaD
Pemetrexed—DHFR—Disease—PSME1—esophageal cancer	7.63e-06	0.000541	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—NOS2—esophageal cancer	7.52e-06	0.000533	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—ALDOB—esophageal cancer	7.46e-06	0.000529	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—NOTCH1—esophageal cancer	7.45e-06	0.000528	CbGpPWpGaD
Pemetrexed—DHFR—Disease—CALR—esophageal cancer	7.32e-06	0.000519	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—ALDH2—esophageal cancer	7.27e-06	0.000516	CbGpPWpGaD
Pemetrexed—ATIC—Metabolism—CREBBP—esophageal cancer	7.26e-06	0.000515	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—GAPDH—esophageal cancer	7.18e-06	0.000509	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—PIK3CA—esophageal cancer	7.17e-06	0.000508	CbGpPWpGaD
Pemetrexed—GART—Metabolism—EP300—esophageal cancer	7.13e-06	0.000506	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—CRABP1—esophageal cancer	7.12e-06	0.000505	CbGpPWpGaD
Pemetrexed—DHFR—Disease—FBXW7—esophageal cancer	7.08e-06	0.000502	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle—RB1—esophageal cancer	7.03e-06	0.000499	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—TP53—esophageal cancer	6.94e-06	0.000492	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—GSTT1—esophageal cancer	6.92e-06	0.000491	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle, Mitotic—CDKN2A—esophageal cancer	6.91e-06	0.00049	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle, Mitotic—RB1—esophageal cancer	6.86e-06	0.000487	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—CYP1B1—esophageal cancer	6.86e-06	0.000486	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—CYP2A6—esophageal cancer	6.84e-06	0.000485	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—GNG7—esophageal cancer	6.77e-06	0.00048	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—CREBBP—esophageal cancer	6.75e-06	0.000479	CbGpPWpGaD
Pemetrexed—TYMS—Circadian rythm related genes—TP53—esophageal cancer	6.66e-06	0.000472	CbGpPWpGaD
Pemetrexed—ATIC—Metabolism—NOS3—esophageal cancer	6.5e-06	0.000461	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—ENO1—esophageal cancer	6.48e-06	0.00046	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—PTGS1—esophageal cancer	6.48e-06	0.00046	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—CYP19A1—esophageal cancer	6.45e-06	0.000457	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—PSME2—esophageal cancer	6.39e-06	0.000453	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—PSME1—esophageal cancer	6.39e-06	0.000453	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—ALDH2—esophageal cancer	6.35e-06	0.00045	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle—CDKN2A—esophageal cancer	6.18e-06	0.000438	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—RB1—esophageal cancer	6.14e-06	0.000435	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—NOS3—esophageal cancer	6.05e-06	0.000429	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—GSTT1—esophageal cancer	6.04e-06	0.000428	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle, Mitotic—CDKN2A—esophageal cancer	6.03e-06	0.000428	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—CYP2A6—esophageal cancer	5.97e-06	0.000423	CbGpPWpGaD
Pemetrexed—ATIC—Metabolism—PTGS2—esophageal cancer	5.95e-06	0.000422	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—HMOX1—esophageal cancer	5.88e-06	0.000417	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle, Mitotic—CCND1—esophageal cancer	5.84e-06	0.000414	CbGpPWpGaD
Pemetrexed—DHFR—Disease—TGFBR2—esophageal cancer	5.72e-06	0.000406	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—CREBBP—esophageal cancer	5.66e-06	0.000401	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—ERBB2—esophageal cancer	5.66e-06	0.000401	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—ENO1—esophageal cancer	5.66e-06	0.000401	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—PTGS1—esophageal cancer	5.66e-06	0.000401	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle, Mitotic—CDKN1A—esophageal cancer	5.65e-06	0.000401	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—ABCB1—esophageal cancer	5.65e-06	0.0004	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—PSME2—esophageal cancer	5.57e-06	0.000395	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—PSME1—esophageal cancer	5.57e-06	0.000395	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—PTGS2—esophageal cancer	5.53e-06	0.000392	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—CYP1B1—esophageal cancer	5.51e-06	0.000391	CbGpPWpGaD
Pemetrexed—DHFR—Disease—SMAD4—esophageal cancer	5.42e-06	0.000384	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—CDKN2A—esophageal cancer	5.39e-06	0.000383	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle, Mitotic—EP300—esophageal cancer	5.38e-06	0.000381	CbGpPWpGaD
Pemetrexed—GART—Metabolism—PIK3CA—esophageal cancer	5.28e-06	0.000374	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle—CCND1—esophageal cancer	5.22e-06	0.00037	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—CYP19A1—esophageal cancer	5.18e-06	0.000367	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle, Mitotic—CCND1—esophageal cancer	5.1e-06	0.000362	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—NOS3—esophageal cancer	5.06e-06	0.000359	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle—CDKN1A—esophageal cancer	5.05e-06	0.000358	CbGpPWpGaD
Pemetrexed—ATIC—Metabolism—EP300—esophageal cancer	4.95e-06	0.000351	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle, Mitotic—CDKN1A—esophageal cancer	4.93e-06	0.00035	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—CDKN1A—esophageal cancer	4.83e-06	0.000343	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—CYP1B1—esophageal cancer	4.81e-06	0.000341	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle—EP300—esophageal cancer	4.81e-06	0.000341	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—HMOX1—esophageal cancer	4.73e-06	0.000335	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle, Mitotic—EP300—esophageal cancer	4.69e-06	0.000333	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle, Mitotic—MYC—esophageal cancer	4.69e-06	0.000332	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—PTGS2—esophageal cancer	4.63e-06	0.000329	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—EP300—esophageal cancer	4.6e-06	0.000326	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—CCND1—esophageal cancer	4.56e-06	0.000323	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—ABCB1—esophageal cancer	4.54e-06	0.000322	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—CYP19A1—esophageal cancer	4.52e-06	0.000321	CbGpPWpGaD
Pemetrexed—DHFR—Disease—HIF1A—esophageal cancer	4.43e-06	0.000314	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—CDKN1A—esophageal cancer	4.41e-06	0.000313	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—EP300—esophageal cancer	4.2e-06	0.000298	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle—MYC—esophageal cancer	4.19e-06	0.000297	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—HMOX1—esophageal cancer	4.13e-06	0.000293	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle, Mitotic—MYC—esophageal cancer	4.09e-06	0.00029	CbGpPWpGaD
Pemetrexed—DHFR—Disease—NOS2—esophageal cancer	4.03e-06	0.000286	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—MYC—esophageal cancer	4.01e-06	0.000284	CbGpPWpGaD
Pemetrexed—DHFR—Disease—NOTCH1—esophageal cancer	3.99e-06	0.000283	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—ABCB1—esophageal cancer	3.96e-06	0.000281	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—EGFR—esophageal cancer	3.92e-06	0.000278	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—EP300—esophageal cancer	3.85e-06	0.000273	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—CREBBP—esophageal cancer	3.77e-06	0.000268	CbGpPWpGaD
Pemetrexed—ATIC—Metabolism—PIK3CA—esophageal cancer	3.66e-06	0.000259	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—MYC—esophageal cancer	3.66e-06	0.000259	CbGpPWpGaD
Pemetrexed—DHFR—Disease—CREBBP—esophageal cancer	3.62e-06	0.000257	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle—TP53—esophageal cancer	3.44e-06	0.000244	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—PIK3CA—esophageal cancer	3.4e-06	0.000241	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—NOS3—esophageal cancer	3.38e-06	0.00024	CbGpPWpGaD
Pemetrexed—DHFR—Disease—NOS3—esophageal cancer	3.24e-06	0.00023	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—PTGS2—esophageal cancer	3.09e-06	0.000219	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—CREBBP—esophageal cancer	3.03e-06	0.000215	CbGpPWpGaD
Pemetrexed—DHFR—Disease—ERBB2—esophageal cancer	3.03e-06	0.000215	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—TP53—esophageal cancer	3e-06	0.000213	CbGpPWpGaD
Pemetrexed—DHFR—Disease—PTGS2—esophageal cancer	2.97e-06	0.00021	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—PIK3CA—esophageal cancer	2.85e-06	0.000202	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—NOS3—esophageal cancer	2.72e-06	0.000193	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—CREBBP—esophageal cancer	2.65e-06	0.000188	CbGpPWpGaD
Pemetrexed—DHFR—Disease—CDKN1A—esophageal cancer	2.59e-06	0.000184	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—EP300—esophageal cancer	2.57e-06	0.000182	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—PTGS2—esophageal cancer	2.48e-06	0.000176	CbGpPWpGaD
Pemetrexed—DHFR—Disease—EP300—esophageal cancer	2.47e-06	0.000175	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—NOS3—esophageal cancer	2.37e-06	0.000168	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—PTGS2—esophageal cancer	2.17e-06	0.000154	CbGpPWpGaD
Pemetrexed—DHFR—Disease—MYC—esophageal cancer	2.15e-06	0.000152	CbGpPWpGaD
Pemetrexed—DHFR—Disease—EGFR—esophageal cancer	2.1e-06	0.000149	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—EP300—esophageal cancer	2.07e-06	0.000146	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—PIK3CA—esophageal cancer	1.9e-06	0.000135	CbGpPWpGaD
Pemetrexed—DHFR—Disease—PIK3CA—esophageal cancer	1.82e-06	0.000129	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—EP300—esophageal cancer	1.8e-06	0.000128	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—PIK3CA—esophageal cancer	1.53e-06	0.000108	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—PIK3CA—esophageal cancer	1.33e-06	9.46e-05	CbGpPWpGaD
